As for the atypical HUS, plasma exchange was the historical standard, but the advent of eculizumab, a monoclonal antibody that inhibits terminal complement activation (C5), and the more recent, ravulizumab, a next-generation long acting C5 inhibitor, has revolutionized management and dramatically improved outcomes (128). The gene discussed is C5; the disease is hemolytic-uremic syndrome.